Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys, Agilent Partner to Resell Each Other's Software to Pharma

NEW YORK (GenomeWeb News) - Accelrys and Agilent Technologies said yesterday that they have struck an agreement to resell each other's software to pharmaceutical companies through an integration and licensing agreement.
Under the agreement, Accelrys will resell Agilent's OpenLAB enterprise content manager, Kalabie electronic lab notebook, and GeneSpring gene expression software. Agilent will resell Accelrys' Accord cheminformatics solutions and Pipeline Pilot scientific operating platform.
"Agilent's strength in laboratory Informatics, QA/QC, and manufacturing are a natural complement to Accelrys' expertise in research, early development, and scientific data management," said Accelrys CEO Mark Emkjer.
Agilent's vice president and general manager, Bruce von Herrmann, said the integrated license and joint resale deal will benefit pharmaceutical clients "that want to spend less time integrating existing informatics solutions and more time developing new, more effective medicines."
Financial terms of the agreement were not released.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.